C4XD, e-therapeutics identify new ways to discover potential Packinson Disease treatments
Source - SMW
C4X Discovery Holdings and e-therapeutics said Thursday they had identified novel approaches to drug targets for the potential treatment of Parkinson's Disease.
Both companies said further work in this area had 'the potential to transform the treatment landscape for these patients.'
'Following the identification of novel drug targets for the treatment of PD from the direct findings from our Taxonomy3 platform we recognise there still remains untapped potential in this proprietary analysis,' said Craig Fox, Chief Scientific Officer at C4XD.
'By working with the team at e-therapeutics and utilising their NDD platform, we have been able to access cutting-edge mathematical and data analysis techniques to augment and interrogate the vast amount of biological information currently available in both public and private databases. This combination has identified additional novel biological pathways for the treatment of PD and we look forward to moving these findings forward to initiate new drug discovery programmes.'
At 8:11am: (LON:C4XD) C4x Discovery Holdings Plc share price was 0p at 72.5p